The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic

Clostridioides difficile infection (CDI) causes substantial morbidity and mortality worldwide with limited antibiotic treatment options. Ridinilazole is a precision bisbenzimidazole antibiotic being developed to treat CDI and reduce unacceptably high rates of infection recurrence in patients. ABSTRACT Clostridioides difficile infection (CDI) causes substantial morbidity and mortality worldwide with limited antibiotic treatment options. Ridinilazole is a precision bisbenzimidazole antibiotic being developed to treat CDI and reduce unacceptably high rates of infection recurrence in patients. Although in late clinical development, the precise mechanism of action by which ridinilazole elicits its bactericidal activity has remained elusive. Here, we present conclusive biochemical and structural data to demonstrate that ridinilazole has a primary DNA binding mechanism, with a co-complex structure confirming binding to the DNA minor groove. Additional RNA-seq data indicated early pleiotropic changes to transcription, with broad effects on multiple C. difficile compartments and significant effects on energy generation pathways particularly. DNA binding and genomic localization was confirmed through confocal microscopy utilizing the intrinsic fluorescence of ridinilazole upon DNA binding. As such, ridinilazole has the potential to be the first antibiotic approved with a DNA minor groove binding mechanism of action.

[1]  S. Neidle,et al.  The mechanism of resistance in Escherichia coli to ridinilazole and other antibacterial head-to-head bis-benzimidazole compounds , 2022, Medicinal Chemistry Research.

[2]  D. Enoch,et al.  Risk of complications and mortality following recurrent and non-recurrent Clostridioides difficile infection: a retrospective, observational, database study in England. , 2020, The Journal of hospital infection.

[3]  Kyongbum Lee,et al.  Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids , 2020, American journal of physiology. Gastrointestinal and liver physiology.

[4]  Antibiotic resistance threats in the United States, 2019 , 2019 .

[5]  S. Wingett,et al.  FastQ Screen: A tool for multi-genome mapping and quality control , 2018, F1000Research.

[6]  Simon Andrews,et al.  FastQ Screen: A tool for multi-genome mapping and quality control , 2018, F1000Research.

[7]  D. Snydman,et al.  Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin , 2018, PloS one.

[8]  D. Snydman,et al.  Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin , 2018, The Journal of antimicrobial chemotherapy.

[9]  R. Thanissery,et al.  Inhibition of spore germination, growth, and toxin activity of clinically relevant C. difficile strains by gut microbiota derived secondary bile acids. , 2017, Anaerobe.

[10]  Ioannis A Kakadiaris,et al.  A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile. , 2016, Anaerobe.

[11]  Aaron T. L. Lun,et al.  From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline , 2016, F1000Research.

[12]  Nicholas K. Sauter,et al.  Diffraction-geometry refinement in the DIALS framework , 2016, Acta crystallographica. Section D, Structural biology.

[13]  S. Neidle,et al.  The discovery of a novel antibiotic for the treatment of Clostridium difficile infections: a story of an effective academic–industrial partnership , 2015, MedChemComm.

[14]  M. Wilcox,et al.  In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile , 2015, The Journal of antimicrobial chemotherapy.

[15]  M. Olsen,et al.  Recurrent Clostridium difficile infection is associated with increased mortality. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[17]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[18]  S. Neidle,et al.  Antibacterial activity of head-to-head bis-benzimidazoles. , 2013, International journal of antimicrobial agents.

[19]  Weijun Luo,et al.  Pathview: an R/Bioconductor package for pathway-based data integration and visualization , 2013, Bioinform..

[20]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[21]  S. Neidle,et al.  Small-molecule binding to the DNA minor groove is mediated by a conserved water cluster. , 2013, Journal of the American Chemical Society.

[22]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[23]  A. Sonenshein,et al.  The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile. , 2011, Microbiology.

[24]  N. Socci,et al.  Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. , 2010, The Journal of clinical investigation.

[25]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[26]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[27]  Andrew J. Hampshire,et al.  Footprinting: a method for determining the sequence selectivity, affinity and kinetics of DNA-binding ligands. , 2007, Methods.

[28]  S. Bhattacharya,et al.  An experimental and computational analysis on the differential role of the positional isomers of symmetric bis-2-(pyridyl)-1H-benzimidazoles as DNA binding agents. , 2007, The Journal of organic chemistry.

[29]  William T. Self,et al.  Analysis of Proline Reduction in the Nosocomial Pathogen Clostridium difficile , 2006, Journal of bacteriology.

[30]  G. Parkinson,et al.  A new class of symmetric bisbenzimidazole-based DNA minor groove-binding agents showing antitumor activity. , 2001, Journal of medicinal chemistry.

[31]  M. Waring,et al.  DNA structural variations produced by actinomycin and distamycin as revealed by DNAase I footprinting. , 1984, Nucleic acids research.

[32]  C. Kelly.  Can we identify patients at high risk of recurrent Clostridium difficile infection? , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[33]  M. Waring,et al.  High-resolution footprinting studies of drug-DNA complexes using chemical and enzymatic probes. , 2001, Methods in enzymology.

[34]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..